Clinical trials

Condition   Drug Name  
Study CYT-003-QbG-10 in atopic dermatitis
Design Randomized; Double-blind
Patients 36
Treatment Regimen CYT-003-QbG-10, 300 µg s.c. 1x/wk x 6; Placebo
Conclusions A phase IIa study of CYT-003-QbG-10 demostrated the safety and good tolerability of the compound, althrough it had no effects in patients with atopic dermatitis
Reference(s) Cytos Biotechnology reports results from phase IIa study with CYT003-QbG10 in patients suffering from atopic dermatitis
Cytos Biotechnology Press Release 2007